Overview

Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.

Simplify's Take

What believers are saying

• Premji Invest praises real-time tracking of cell changes under drugs or cytokines in 2023.
• Enables neuron network studies with signaling across enclosure walls preserving viability.
• Integrates fluorescence imaging, RNA-Seq, and AI morphotyping in unified workflows.

What critics are saying

• 10x Genomics captures 80% market share, undercutting Cellanome via throughput and pharma partnerships.
• Bruker lawsuit filed January 2026 infringes microfluidic patents, halts sales and drains $15M.
• Revvity's SLAS 2026 system poaches Genentech with 5x faster workflow and lower pricing.

What makes Cellanome unique

• CellCage technology isolates live cells in tunable micro-environments for longitudinal imaging and transcriptomics.
• R3200 platform uses AI segmentation and micro-3D printing to form thousands of enclosures in under 15 minutes.
• Supports parallel flow cell lanes for precise washout, pulsing, and sequential dosing unlike plate systems.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$201M

Above

Industry Average

Funded Over

2 Rounds

$150,000,000

Series B

Jan 2024

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.

Series B Funding Comparison

Above Average

Industry standards

Ind Avg. $35M

$4M

$30M

$45M

$65M

$100M

$150M

View all funding stages